Reduction in distractibility with AF102B and THA in the macaque

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 2, 2003, Pages 301-306

  O'Neill, Joseph ^a   Siembieda, Douglas W ^b   Crawford, K Casey ^b   Halgren, Eric ^c   Fisher, Abraham ^d   Fitten, L Jaime ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b West Los Angeles Medical Center   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AF102B; Cholinesterase inhibitors; Distractibility; Monkeys; Muscarinic agonists; THA

Indexed keywords

CEVIMELINE; CHOLINESTERASE INHIBITOR; MUSCARINIC AGENT; TACRINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DISTRACTIBILITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EYE TRACKING; MACACA; MONKEY; NONHUMAN; PRIORITY JOURNAL; REACTION TIME; TASK PERFORMANCE; TITRIMETRY; VISUAL STIMULATION;

MACACA RADIATA; PRIMATES;

EID: 0242352332     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.08.006     Document Type: Article

References (51)

1. Addington J., Addington D., Gasbarre L. Distractibility and symptoms in schizophrenia. J. Psychiatry Neurosci. 22:1997;180-184.
2. Adem A., Mohammed A.K., Winblad B. Multiple effects of tetrahydroaminoacridine on the cholinergic system: biochemical and behavioural aspects. J. Neural Transm. 2:1990;113-128.
3. Bartolomeo A.C., Morris H., Buccafusco J.J., Kille N., Rosenzweig-Lipson S., Husbands M.G.et al. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J. Pharmacol. Exp. Ther. 292:2000;584-596.
4. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
5. Chelliah J., Smith J.D., Fariss M.W. Inhibition of cholinesterase activity by tetrahydroaminoacridine and the hemisuccinate esters of tocopherol and cholesterol. Biochim. Biophys. Acta. 1206(1):1994;17-26.
6. Dalley J.W., McGaughey J., O'Connell M.T., Cardinal R.N., Levita L., Robbins T.W. Distinct changes in cortical acetylcholine and noradrenaline efflux during contingent and noncontingent performance of a visual attentional task. J. Neurosci. 21(13):2001;4908-4914.
7. Davidson M.C., Cutrell E.B., Marrocco R.T. Scopolamine slows the orienting of attention in primates to cued visual targets. Psychopharmacology. 142:1999;1-8.
8. Davis K.L., Thal L.J., Gamzu E.R., Davis C.S., Woolson R.F., Gracon S.I.et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. 327:1992;1253-1259.
9. Dawson G.R., Iversen S.D. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav. Brain Res. 57:1993;143-153.
10. Egorov A.V., Hamam B.N., Fransén E., Hasselmo M.E., Alonso A.A. Graded persistent activity in entorhinal neurons. Nature. 420:2002;173-178.
11. Everitt B.J., Robbins T.W. Central cholinergic systems and cognition. Ann. Rev. Psychol. 48:1997;649-684.
12. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J.A. A controlled trial of tacrine in Alzheimer's disease: the Tacrine Study Group. JAMA. 268:1992;2523-2529.
13. Felder C.C., Bymaster F.P., Ward J., DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 43(23):2000;4333-4353.
14. File S.E. Are central cholinergic paths involved in habituation of exploration and distraction? Pharmacol. Biochem. Behav. 4(6):1976;695-702.
15. Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn. J. Pharmacol. 84(2):2000;101-102.
16. Fisher A., Heldman E., Gurwitz D., Haring R., Karton Y., Meshulam H.et al. M1 agonists for the treatment of Alzheimer's disease: novel properties and clinical update. Ann. N. Y. Acad. Sci. 777:1996;189-196.
17. Fisher A., Brandeis R., Bar-Ner R.H., Kliger-Spatz M., Natan N., Sonego H.et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J. Mol. Neurosci. 19(1-2):2002;145-153.
18. Fitten L.J., Perryman K.M., Gross P.L., Fine H., Cummins J., Marshall C. Treatment of Alzheimer's disease with short and long-term oral THA and lecithin: a double blind study. Am. J. Psychiatry. 147:1990;239-242.
19. Fitten L.J., Perryman K.M., O'Neill J., Halgren E. Influence of cholinesterase inhibitors on cortical slow-wave activity in aging nonhuman primate. Pharmacol. Biochem. Behav. 49:1994;235-239.
20. Frisoni G.B. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. J. Neurol. 248:2001;551-557.
21. Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ. 166(5):2002;616-623.
22. Greenlee W., Clader J., Asberom T., McCombie S., Ford J., Guzik H.et al. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco. 56:2001;247-250.
23. Grobe J.E., Perkins K.A., Goettler-Good J., Wilson A. Importance of environmental distractors in the effects of nicotine on short-term memory. Exp. Clin. Psychopharmacol. 6(2):1998;209-216.
24. Hahn B., Shoaib M., Stolerman I.P. Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology. 162:2002;129-137.
25. Håkansson L. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Acta Neurol. Scand. Suppl. 149:1993;7-9.
26. Hoyer W.J., Rebok G.W., Sved M.S. Effects of varying irrelevant information on adult age differences in problem solving. J. Gerontol. 34:1979;553-560.
27. Jackson W.J., Buccafusco J.J., Terry A.V., Turk D.J., Rush D.K. Velnacrine maleate improves delayed matching performance by aged monkeys. Psychopharmacology. 119:1995;391-398.
28. Jessen F., Kucharski C., Fries T., Papassotiropoulos A., Hoenig K., Maier W.et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am. J. Psychiatry. 158:2001;1319-1321.
29. Korcyn A.D. Muscarinic M(1) agonists in the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs. 9(10):2000;2259-2267.
30. Lawrence A.D., Sahakian B.J. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis. Assoc. Disord. 9(Suppl. 2):1995;43-49.
31. Madden D.J. Selective attention and visual search. J. Exp. Psychol. Hum. Percept. Perform. 18:1992;821-836.
32. Mapstone M., Rösler A., Hays A., Gitelman D.R., Weintraub S. Dynamic allocation of attention in aging and Alzheimer disease: uncoupling of the eye and the mind. Arch. Neurol. 58(9):2001;1443-1447.
33. McGaughey J., Everitt B.J., Robbins T.W., Sarter M. The role of cortical cholinergic afferent projections in cognition: impact of new selective neurotoxins. Behav. Brain Res. 115:2000;251-263.
34. Messer W.S. Jr. Cholinergic agonists and the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 2(4):2002;353-358.
35. Ogura H., Aigner T.G. MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs. J. Pharmacol. Exp. Ther. 266(1):1993;60-64.
36. O'Neill J., Fitten L.J., Siembieda D.W., Crawford K.C., Halgren E., Fisher A.et al. Divided attention-enhancing effects of AF102B and THA in aging monkeys. Psychopharmacology. 143:1999;123-130.
37. O'Neill J., Halgren E., Marinkovic K., Siembieda D.W., Refai D., Fitten L.J.et al. Effects of muscarinic and adrenergic agonism on auditory P300 in the macaque. Physiol. Behav. 70(1-2):2000;163-170.
38. Parasuraman R., Greenwood P.M., Haxby J.V., Grady C.L. Visuospatial attention in dementia of the Alzheimer type. Brain. 115:1992;711-733.
39. Passetti F., Dalley J.W., O'Connell M.T., Everitt B.J., Robbins T.W. Increased acetylcholine release in the rat medial prefrontal cortex during performance of a visual attention task. Eur. J. Neurosci. 12:2000;3051-3058.
40. Pickworth W.B., Fant R.V., Butschky M.F., Henningfield J.E. Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pharmacol. Biochem. Behav. 56(2):1997;181-187.
41. Prendergast M.A., Jackson W.J., Terry A.V. Jr., Decker M.W., Arneric S.P., Buccafusco J.J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology. 136:1998;50-58.
42. Robbins T.W. Arousal systems and attentional processes. Biol. Psychiatry. 45:1997;57-71.
43. Sanberg P.R., Silver A.A., Shytle R.D., Philipp M.K., Cahill D.W., Fogelson H.M.et al. Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. 74(1):1997;21-25.
44. Sarter M., Bruno J.P. Cortical cholinergic inputs mediating arousal, attentional processing, and dreaming: differentiating afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience. 95:2000;933-952.
45. Sarter M., Bruno J.P., Givens B., Moore H., McGaughey J., McMahon K. Neuronal mechanisms mediating drug-induced cognition enhancement: cognitive activity as a necessary intervening variable. Brain Res. Cogn. Brain Res. 3:1996;329-343.
46. Soares J.C., Gershon S. THA-historical aspects, review of pharmacological properties and therapeutic effects. Dementia. 6(4):1995;225-234.
47. Talesa V.N. Acetylcholinesterase in Alzheimer's disease. Mech. Ageing Dev. 122:2001;1961-1969.
48. Terry A.V. Jr., Buccafusco J.J., Borsini F., Leusch A. Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine. Psychopharmacology (Berl.). 162(3):2002;292-300.
49. Terry A.V. Jr., Risbrough V.B., Buccafusco J.J., Menzaghi F. Effects of (±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J. Pharmacol. Exp. Ther. 301:2002;284-292.
50. Vincent G.P., Sepinwall J. AF102B, a novel M1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res. 597(2):1992;264-268.
51. Zametkin A.J., Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. New Engl. J. Med. 340:1999;40-46.